

IRVINE SCIENTIFIC AND SELEXIS TO ANNOUNCE RESULTS OF SUCCESSFUL COLLABORATION

Results to be presented at Bioprocess International Conference on October 13

Geneva, Switzerland, and Santa Ana, California, October 12, 2009 – Selexis SA ("Selexis") and Irvine Scientific Inc. ("Irvine") announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs™ and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines. Irvine and Selexis will jointly present the results on Tuesday, October 13, 2009 at 11:45 AM at the BioProcess International Conference 2009 being held in Raleigh, North Carolina. Results of the program demonstrate the ability to produce gram quantities of therapeutic antibodies in 12 weeks using a CHO platform designed specifically for large scale cGMP manufacturing.

"By combining the world class media development capabilities found at Irvine Scientific with the speed and performance of the Selexis SURE Cell Line Development™ program a very powerful CHO based production platform has been developed" said Dr. Igor Fisch, CEO and co-founder of Selexis SA. "This platform can be implemented for the production of large quantities of antibody or recombinant protein useful for preclinical and clinical development purposes, which is beneficial to both our licensees and service clients".

"Our scientists have been able to quickly develop and apply an advanced media program to support the speed and performance of the Selexis system in achieving gram per liter productivities in matter of weeks" said Makoto Shintani, Chief Executive Officer. "It is clear that this program can provide significant benefits to biotech companies in need of large quantities of antibodies or proteins quickly".

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells – Selexis Genetic Elements™. Selexis has further developed platforms, to include: Selexis SUREtech Vectors™, Selexis SUREfection™ Selexis SURE Cell Line Development™ and Selexis INTEGRA-D2M™.



**YOUR PARTNER FOR CELL LINE
DEVELOPMENT**

About Irvine Scientific:

Irvine Scientific, a subsidiary of Japan Energy Corporation, is a worldwide leader in the design, manufacture and distribution of medical devices including Industrial Cell Culture, Cytogenetic, and Assisted Reproductive Technology (ART) products. Irvine Scientific is a large scale producer of advanced and quality cell culture media for the industrial bioprocess and diagnostic markets. The company has extensive experience in the design of culture media leading to significant improvement in biopharmaceutical production yield. The company also manufactures media for medical and stem cell applications.

Irvine Scientific's worldwide distribution channels deliver products to large scale biopharmaceutical industry and to the research and laboratory communities.

For more information contact:

Irvine Scientific

Phone: +949-261-7800

Email tmrequest@irvinesci.com

Selexis

Phone: +41 (0)22 308 93 60

Email: SURE@selexis.com